Beyond Air, Inc. (XAIR)
NASDAQ: XAIR · IEX Real-Time Price · USD
1.215
+0.025 (2.10%)
Apr 19, 2024, 3:48 PM EDT - Market open
Company Description
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States.
The company engages in the development of LungFit platform, a nitric oxide generator and delivery system.
It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.
Beyond Air, Inc. is based in Garden City, New York.
Beyond Air, Inc.
| Country | United States |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 98 |
| CEO | Steven Adam Lisi |
Contact Details
Address: 900 Stewart Avenue, Suite 301 Garden City, New York 11530 United States | |
| Phone | 516-665-8200 |
| Website | beyondair.net |
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001641631 |
| CUSIP Number | 08862L103 |
| ISIN Number | US08862L1035 |
| Employer ID | 47-3812456 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Steven Adam Lisi | Chief Executive Officer and Chairman of the Board |
| Amir Avniel | Co-Founder, President, Chief Business Officer and Director |
| Michael A. Gaul | Chief Operating Officer |
| Douglas Quinton Larson | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Edward Barger | Head of Investor Relations |
| Kori-Ann Taylor | Head of Marketing |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board |
| Dr. Jeff Myers M.D., Ph.D. | Chief Medical Officer |
| Adam Newman | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 424B5 | Filing |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 1, 2024 | 424B5 | Filing |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Feb 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |